MAS825 for Still's disease in children and adults
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new drug called MAS825 for people with Still's disease that is still active despite other treatments. It aims to see if the drug can reduce symptoms like fever, rash, joint pain, or a serious complication called macrophage activation syndrome.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 year old and have a diagnosis of Still's disease.
- Your disease must be active, shown by high CRP or ferritin levels and symptoms like fever, rash, joint inflammation, or other complications.
- You must have tried other biologic treatments and they didn't work well enough or caused side effects.
- You cannot be taking certain other immune-suppressing drugs, and your steroid dose must be within a set limit.
- You must not have serious infections, recent live vaccines, certain cancers, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new biologic medicines (goflikicept and olokizumab) as a second treatment option for people with adult-onset Still's disease. These drugs target inflammation to help control symptoms like fever, rash, and joint pain.
This study collects health information from people with adult-onset Still's disease and similar autoinflammatory conditions to better understand these diseases. By joining, you contribute to research that may lead to better care in the future.
This study looks at Kawasaki disease that gets complicated by a serious immune reaction called macrophage activation syndrome (MAS). It aims to better understand and treat this complication in children.
This is a long-term study that collects health information and lab samples from people who have certain diagnoses of recurring (coming and going) inflammatory fevers and related joint or immune conditions. It may help researchers better understand these diseases and how they work over time.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This study is testing an experimental medicine called PF-08154225 to see if it can help treat several autoimmune conditions, including rheumatoid arthritis, lupus, and related disorders. It might reduce disease activity or symptoms in people who have not found relief from other treatments.
Hear when a new Still´s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.